Entering text into the input field will update the search result below

Rigel Pharmaceuticals' (RIGL) CEO Raul Rodriguez on Q4 2017 Results - Earnings Call Transcript

Mar. 06, 2018 11:11 PM ETRigel Pharmaceuticals, Inc. (RIGL)
SA Transcripts profile picture
SA Transcripts

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q4 2017 Earnings Conference Call March 6, 2018 5:00 PM ET


Dolly Vance - Executive Vice President, Corporate Affairs and General Counsel

Raul Rodriguez - President and Chief Executive Officer

Anne-Marie Duliege - Executive Vice President and Chief Medical Officer

Eldon Mayer - Executive Vice President and Chief Commercial Officer

Nelson Cabatuan - Vice President, Finance


Kyung Yang - Jefferies LLC

Tessa Romero - ‎J.P. Morgan Securities, LLC

Do Kim - BMO Capital Markets Corp.

Joseph Pantginis - H.C. Wainwright & Co.

Elemer Piros - Cantor Fitzgerald & Co.


Good afternoon, and welcome to Rigel Pharmaceuticals' Financial Conference Call for the Fourth Quarter and Year End of 2017. All participants are in a listen-only mode. We will be facilitating a question-and-answer session at the end of today's conference. [Operator Instructions] I would like to remind you that this call is being recorded for replay purposes from Rigel's website. [Operator Instructions]

And now, I would turn this conference over to our first speaker, Dolly Vance, who is Rigel's Executive Vice President, Corporate Affairs and General Counsel.

Dolly Vance

Welcome to our financial results and business update conference call. The financial press release for the fourth quarter and year ended 2017 was issued a short while ago and can be viewed in the News & Events section of our Investor Relations page on our website, www.rigel.com.

Joining me on the call today from Rigel are: Raul Rodriguez, our CEO; Anne-Marie Duliege, our Chief Medical Officer; Eldon Mayer, our Chief Commercial Officer; and Nelson Cabatuan, our VP of Finance.

As a reminder, during today's call, we may make forward-looking statements regarding our financial outlook, and our plans and timings for regulatory and product development. These statements are subject to risks and uncertainties that may cause actual results to differ than

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.